Effect of melatonin on sleep quality in IBD patient

Investigating effect of melatonin on biochemical markers and improving sleep quality in IBD patient

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250205064653N1

Enrollment

Registered

2025-02-27

Start date

2025-03-07

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases.

Interventions

Intervention 1: The group that will receive melatonin. Intervention 2: Control group: will receive a placebo.

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: IBD patients in remission

Exclusion criteria

Exclusion criteria: Patients with a history of seizures , depression , liver failure , renal failure were excluded Patients who did not want to cooperate IV drug abusers , pregnant and lactating women were excluded Nifedipine and Fluvoxamine users were excluded due to interference with melatonin NSAID users were excluded due to interference with fecal calprotectin test

Design outcomes

Primary

Measure	Time frame
Improving patients sleep quality, Improving of biochemical markers including ESR,CRP,FC. Timepoint: Before starting the study and 3 months later. Method of measurement: Pittsburgh Sleep Quality Index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrnoosh Harfsheno

Ahvaz University of Medical Sciences

himam@ajums.ac.ir+98 61 3222 2085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026